Abstract: NAD⁺ metabolism and senescent CD8⁺ T cells in ulcerative colitis
In this abstract, senescent CD8⁺ T cells are described as a pathogenic population that worsens colitis; NAD metabolic dysregulation is proposed to drive their senescence via cGAS-STING, and senolytic treatment attenuated disease severity in the reported work. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract reports senescent CD8 T cells as a distinct pathogenic population that exacerbates colitis. [1]
Systemic senolytic treatment is reported to significantly attenuate disease severity. [1]
The senescent-metabolic signature is reported to correlate with severe disease and predict non-response to biologic therapies in UC patients. [1]
The source at a glance
- Study type / format
- Journal article abstract (research report)
- Population / context
- CD8 T cells and ulcerative colitis, including UC patients mentioned for the biologic non-response correlation
- Summary based on
- Study abstract
- Original publication
- September 1, 2026
Senescent CD8⁺ T cells and colitis severity
The abstract frames immunosenescence as increasingly linked to chronic inflammatory disorders, but says its precise pathogenic contribution to ulcerative colitis (UC) was unclear. The authors report identifying senescent CD8 T cells as a distinct pathogenic population that exacerbates colitis. They also state that systemic senolytic treatment significantly attenuated disease severity. These are findings reported in the abstract; the abstract does not give the animal models, sample sizes or human treatment data behind them.
Supporting source [1]
Proposed NAD–cGAS-STING mechanism of T cell senescence
Mechanistically, the abstract states that NAD (nicotinamide adenine dinucleotide) metabolic dysregulation triggers mitochondrial dysfunction and leakage of mitochondrial DNA into the cytosol. This is said to promote CD8 T cell senescence through activation of the cGAS-STING signaling pathway. Spatial transcriptomic mapping reportedly showed senescent CD8 T cells enriched within mucosal niches with NAD metabolic dysregulation. The abstract presents this as a proposed axis; it does not report experiments that establish causation in human UC.
Supporting source [1]
Biologic non-response link and therapeutic proposal
According to the abstract, the senescent-metabolic signature correlates with severe disease phenotypes and predicts non-response to biologic therapies in UC patients. The authors conclude that a NAD–cGAS-STING axis drives T cell senescence and that clearing senescent immune cells is a promising therapeutic strategy for UC. This is a proposal based on the reported work, not a validated treatment. The abstract does not state how many patients were studied, which biologics were involved, or how prediction was assessed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report study design details, sample sizes, which species or models were used, follow-up, or how the prediction of biologic non-response was assessed. The mechanistic axis and the senolytic strategy are presented as proposals, not validated treatments.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ye M, Zhou Q, Kong M, Zhao S, Lin L, Chen L, Yu J, Luo F, Liu J, Zhang J. · europepmc.org · September 1, 2026